This HTML5 document contains 92 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/chebi/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/mixture/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/kegg-compound/
n28http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/pubchem-substance/
n12http://www.rxlist.com/cgi/generic/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/iuphar/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/guide-to-pharmacology/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/national-drug-code-directory/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00687/identifier/chemspider/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00687
rdf:type
n3:Drug
n3:description
A synthetic mineralocorticoid with anti-inflammatory activity. [PubChem]
n3:dosage
n27:271B4552-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
3.5 hours
n3:indication
For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
n3:manufacturer
n5:271B454C-363D-11E5-9242-09173F13E4C5 n5:271B454B-363D-11E5-9242-09173F13E4C5 n5:271B454A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00687 n28:DB00687
dcterms:title
Fludrocortisone
adms:identifier
n7:PA164743961 n13:42291-529-01 n14:2873 n15:C07004 n16:31378 n17:46508616 n18:50885 n19:2873 n21:29111 n22:DB00687 n30:Fludrocortisone
n3:mechanismOfAction
Fludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises extracellular fluid volume and blood pressure and lowers potassium levels.
n3:packager
n5:271B4549-363D-11E5-9242-09173F13E4C5 n5:271B4546-363D-11E5-9242-09173F13E4C5 n5:271B4547-363D-11E5-9242-09173F13E4C5 n5:271B4542-363D-11E5-9242-09173F13E4C5 n5:271B4543-363D-11E5-9242-09173F13E4C5 n5:271B4540-363D-11E5-9242-09173F13E4C5 n5:271B4541-363D-11E5-9242-09173F13E4C5 n5:271B453F-363D-11E5-9242-09173F13E4C5 n5:271B4548-363D-11E5-9242-09173F13E4C5 n5:271B4544-363D-11E5-9242-09173F13E4C5 n5:271B453C-363D-11E5-9242-09173F13E4C5 n5:271B4545-363D-11E5-9242-09173F13E4C5 n5:271B453D-363D-11E5-9242-09173F13E4C5 n5:271B453E-363D-11E5-9242-09173F13E4C5
n3:synonym
9alpha-FLUOROCORTISOL Fludrocortison Fludrocortisona Fludrocortisonum Fludrocortisone Fluohydrocortisone
n3:toxicity
Effects of overexposure include irritation, cardiac edema, increased blood volume, hypertension, cardiac arrhythmias, enlargement of the heart, headaches, and weakness of the extremities.
n8:hasAHFSCode
n9:68-04-00
n3:foodInteraction
Take with food to reduce irritation. Avoid excess salt/sodium unless otherwise instructed by your physician.
n3:mixture
n29:271B453B-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
High
n3:salt
n3:synthesisReference
U.S. Patent 2,957,013
foaf:page
n11:fludrocortisone.html n12:fludro.htm
n3:IUPAC-Name
n4:271B4557-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B455D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B455C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4559-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B455A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B455B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4555-363D-11E5-9242-09173F13E4C5 n4:271B456D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4556-363D-11E5-9242-09173F13E4C5 n4:271B4553-363D-11E5-9242-09173F13E4C5 n4:271B456E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4554-363D-11E5-9242-09173F13E4C5 n4:271B456F-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n20:H02AA02
n3:H-Bond-Acceptor-Count
n4:271B4563-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4564-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B455E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B455F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4561-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4560-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4562-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
127-31-1
n3:category
n3:containedIn
n26:271B454D-363D-11E5-9242-09173F13E4C5 n26:271B4550-363D-11E5-9242-09173F13E4C5 n26:271B4551-363D-11E5-9242-09173F13E4C5 n26:271B454E-363D-11E5-9242-09173F13E4C5 n26:271B454F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4569-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B456B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B456C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4568-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4567-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B456A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4558-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4565-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4566-363D-11E5-9242-09173F13E4C5